Press Releases Items Per Page 102550 News Category FinancialGeneral Year None2018201720162015201420132012201120102009200820072006 Nektar Therapeutics Announces Ten Abstracts Accepted for Presentation at the 2018 Society for Immunotherapy of Cancer (SITC) Annual Meeting Oct 02, 2018 Nektar Therapeutics Strengthens Board of Directors with Appointment of Veteran Biotechnology Executive Karin Eastham Oct 01, 2018 Nektar Therapeutics Reports Financial Results for the Second Quarter of 2018 Aug 08, 2018 Nektar to Announce Financial Results for the Second Quarter 2018 on Wednesday, August 8, 2018, After Close of U.S.-Based Financial Markets Aug 01, 2018 Nektar Therapeutics Announces New Drug Application for NKTR-181 Accepted for Review by FDA Jul 30, 2018 New Data for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Low Back Pain in Adult Patients New to Opioid Therapy, Presented at College on Problems of Drug Dependence 80th Annual Scientific Meeting Jun 14, 2018 Nektar to Webcast Presentation at the Jefferies 2018 Healthcare Conference in New York Jun 05, 2018 Preliminary Data for NKTR-214 in Combination with Opdivo (nivolumab) for Patients with Stage IV Metastatic Melanoma, Renal Cell Carcinoma, and Urothelial Cancers Presented at ASCO 2018 Jun 02, 2018 Nektar Therapeutics Announces Submission of a New Drug Application to the U.S. FDA for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Low Back Pain in Adult Patients New to Opioid Therapy May 31, 2018 Syndax and Nektar Therapeutics Announce Immuno-Oncology Clinical Trial Collaboration May 30, 2018 Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »